Insights

Clinical momentum Metaclipse is a clinical stage biotech advancing Membrex™ immunotherapy with ongoing Phase 1 trials in triple negative breast cancer and head and neck cancer, indicating a near-term collaboration or trial sponsorship opportunity for oncology-focused partners.

Vaccine focus The company has recently pursued COVID-19 and influenza vaccine development leveraging biological adjuvants, suggesting potential partnerships or licensing discussions with vaccine manufacturers, public health entities, or contract development organizations.

Funding signals Publicized grant activity from NIAID and milestones in infectious disease vaccine programs imply a favorable funding runway and credibility to attract co-development, grant funding, or milestone-based collaboration from strategic investors.

Scale considerations With a small team size and revenue in the lower end of the scale, there may be high value in channeling partnerships that provide development acceleration, clinical trial funding, or manufacturing support to accelerate timelines.

Competitive positioning As a niche player focusing on biological adjuvants for immunotherapies and vaccines, Metaclipse could be positioned for partnerships with larger biotechs or CROs seeking novel adjuvant platforms to augment their oncology or infectious disease pipelines.

Similar companies to Metaclipse Therapeutics Corporation

Metaclipse Therapeutics Corporation Tech Stack

Metaclipse Therapeutics Corporation uses 8 technology products and services including Joomla, WordPress, Microsoft 365, and more. Explore Metaclipse Therapeutics Corporation's tech stack below.

Metaclipse Therapeutics Corporation's Email Address Formats

Metaclipse Therapeutics Corporation uses at least 4 email formats:
Metaclipse Therapeutics Corporation Email FormatsExamplePercentage
FLast@metaclipsetherapeutics.comJDoe@metaclipsetherapeutics.com
94%
FMLast@metaclipsetherapeutics.comJMDoe@metaclipsetherapeutics.com
6%
FLast@metaclipse.comJDoe@metaclipse.com
78%
Last@metaclipse.comDoe@metaclipse.com
22%

Frequently Asked Questions

What is Metaclipse Therapeutics Corporation's phone number?

Minus sign iconPlus sign icon
You can contact Metaclipse Therapeutics Corporation's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Metaclipse Therapeutics Corporation's official website and social media links?

Minus sign iconPlus sign icon
Metaclipse Therapeutics Corporation's official website is metaclipse.com and has social profiles on LinkedIn.

How much revenue does Metaclipse Therapeutics Corporation generate?

Minus sign iconPlus sign icon
As of November 2026, Metaclipse Therapeutics Corporation's annual revenue is estimated to be $1M - $10M.

What is Metaclipse Therapeutics Corporation's SIC code and NAICS code?

Minus sign iconPlus sign icon
Metaclipse Therapeutics Corporation's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Metaclipse Therapeutics Corporation have currently?

Minus sign iconPlus sign icon
As of November 2026, Metaclipse Therapeutics Corporation has approximately 11 employees across 1 continents, including North America. Key team members include Metaclipse Therapeutics: M. T. Explore Metaclipse Therapeutics Corporation's employee directory with LeadIQ.

What industry does Metaclipse Therapeutics Corporation belong to?

Minus sign iconPlus sign icon
Metaclipse Therapeutics Corporation operates in the Biotechnology Research industry.

What technology does Metaclipse Therapeutics Corporation use?

Minus sign iconPlus sign icon
Metaclipse Therapeutics Corporation's tech stack includes Joomla, WordPress, Microsoft 365, SendGrid, Google Cloud, Modernizr, WP Engine and waitForImages.

What is Metaclipse Therapeutics Corporation's email format?

Minus sign iconPlus sign icon
Metaclipse Therapeutics Corporation's email format typically follows the pattern of FLast@metaclipsetherapeutics.com. Find more Metaclipse Therapeutics Corporation email formats with LeadIQ.

When was Metaclipse Therapeutics Corporation founded?

Minus sign iconPlus sign icon
Metaclipse Therapeutics Corporation was founded in 2012.
Metaclipse Therapeutics Corporation logo

Metaclipse Therapeutics Corporation

Biotechnology ResearchTexas, United States11-50 Employees

Metaclipse Therapeutics Corporation is a clinical-stage biotechnology company focused on immune-based therapies for cancer and vaccines to prevent infectious diseases, leveraging proprietary biological adjuvants. Its personalized immunotherapy platform, Membrex, has produced encouraging preclinical results across several solid tumors, with Phase 1 trials underway for triple-negative breast cancer and head and neck cancer (HNSCC). The work seeks to address unmet needs in oncology and vaccinology through innovative use of adjuvants in both therapeutic and preventive vaccines.

Based in Houston, Texas, the firm operates with a small team within the biotechnology research sector. Its programs target cancer patients and infectious disease prevention, aiming to offer new immunotherapy options and vaccines for broader clinical use. Public notices from 2020 indicate activity in developing a COVID-19 vaccine and an influenza vaccine using a virus-like particle approach, reflecting ongoing exploratory work in its infectious disease portfolio.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2012
Employees
11-50

Section iconFunding & Financials

  • $1M - $10M

    Metaclipse Therapeutics Corporation's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.